Shire plc

Delisted

CIK 936402fmd_11ZNDV8X1XRKWC290W02MQGRX0Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2007 to Sep 30, 2018, 43 periods

Income Statement · Annual · Millions · USD
Line item	FY2008	FY2009	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017
Total revenues	3,022	3,008	3,471	4,158	4,527	4,934	6,022	6,417	11,397	15,161
Cost of revenue	408	388	463	552	586	671	979	969	3,817	4,701
Net interest income	–	–	–	–	–	–	(6)	(37)	(451)	(569)
Gross profit	2,614	2,620	3,008	3,606	3,942	4,264	5,043	5,448	7,580	10,460
Research and development	494	640	662	765	953	933	1,068	1,564	1,440	1,763
Selling, general and administrative	1,455	1,343	1,526	1,676	1,948	1,499	1,782	1,843	3,015	3,531
Total operating expenses	2,610	2,388	2,677	3,022	3,482	3,201	4,324	4,997	10,434	12,705
Operating income	412	620	794	1,136	1,045	1,734	1,698	1,420	963	2,455
Interest expense	139	40	35	39	38	38	31	42	470	579
Other non-operating income (expense)	(146)	23	(25)	(19)	(37)	(40)	1,638	(34)	(477)	(562)
Income before taxes	266	643	769	1,117	1,008	1,694	3,336	1,386	486	1,893
Income tax expense	98	139	183	237	203	278	56	46	(126)	(2,358)
Net income from continuing operations	170	504	588	883	806	1,420	3,283	1,338	604	4,254
Net income	156	492	588	865	745	665	3,406	1,303	327	4,272
Net income to common shareholders	156	492	622	899	777	693	3,406	–	–	–